Discovery Stems From Here

Atrial fibrillation is the most common arrhythmia observed in the clinic, affecting 6 million patients in Europe and accounting for 30% of strokes. The prevalence of atrial fibrillation continues to grow due to an aging population and is expected to double over the next 50 years. Given the need to develop safer and more effective anti-arrhythmic therapeutics, considerable efforts have been made to understand the cellular mechanisms of the disease and translate this knowledge into innovative treatments.

The rapid development of induced pluripotent stem cell-derived cells (iPSCs) is set to revolutionise modern drug discovery through the increased utilisation of human cell reagents in research.

Until recently, despite being the most prominent cell type in the human brain, research on astrocytes has been overshadowed by neurons. Once thought to only provide structural support to neurons it has become clear that astrocytes are a vastly heterogenous population of cells with varied functions and roles to match.

We are delighted to announce plans to open a new operational hub in the United States. The site will open in the fall of 2018 and will help to support Axol’s customer base in the United States and Canada.

Cambridge, UK – (17th July 2018) – Axol Bioscience, the human cell culture specialists, provide highly validated primary cells and iPSC-derived cells together with optimised media and growth supplements, launch their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease.